Company ProfilePremium

Vivimed Labs Ltd

Company Profile Analysis

Ticker: VIVIMEDLAB.NS

ESOMAR 23 Corporate BadgeISO Certifications Badge
Vivimed Labs Ltd - Company showcase

Year Founded & Workforce

1988

552 Employees

Vivimed Labs Ltd logo

Vivimed Labs Ltd Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Vivimed Labs Ltd Overview

Identity table

FieldDetailSource
Legal nameVivimed Labs LimitedExchange filings 2026
Former namesEmgi Pharmaceuticals & Chemicals Pvt Ltd (incorporated 22 Sep 1988); converted to public company and renamed Emgi Pharmaceuticals & Chemicals Ltd (21 Apr 1994); renamed Vivimed Labs Limited (22 Apr 1997)Company background (Arihant Capital company profile)
Founding / incorporation22 September 1988 (some aggregators cite 1991 as founding; the statutory incorporation date is 1988)MCA/CIN; aggregator profiles conflict
CINL02411KA1988PLC009465Form G (June 2026)
PANAAACV6060AForm G (June 2026)
Incorporation jurisdictionKarnataka, India (Registrar of Companies, Bangalore)MCA records
Registered officePlot No. 78-A, Kolhar Industrial Area, Bidar, Karnataka – 585403, IndiaForm G (June 2026)
Corporate office3rd Floor, 6-3-866/1/G1, Greenlands, Begumpet, Hyderabad, Telangana – 500016, India (per company letterhead on exchange filings)NSE disclosure 13 Feb 2026
Stock exchanges / tickersBSE: 532660; NSE: VIVIMEDLAB (currently traded in "BE" series, trade-for-trade settlement); also referenced by Metropolitan Stock Exchange (MSE)NSE circular 10 Dec 2025; MSE circular 17 Dec 2025
ISININE526G01021NSE circular
LEI335800LYN9TN3F87WV86Financialfilings.com index
CUSIPNot applicable (no US listing)—
Face valueINR 2 per share (historically INR 10)NSE circular 10 Dec 2025
Shares outstanding~82.93 million (FY2026)S&P Global via StockAnalysis
Fiscal year end31 MarchFilings
Employees (latest)552 (per Form G, June 2026); 586 cited by PitchBookForm G; PitchBook
Employee trend (3-year)Not publicly disclosed in verified form—
Statutory auditorSVRL & Co., Chartered Accountants (qualified opinions on FY2025 and FY2026)FY2026 results coverage; FY2025 auditor report
Market capitalisation (current)~INR 54.7 crore (INR 547 million) at INR 6.59 close on 7 Oct 2026 × 82.93M shares (analyst calculation)StockAnalysis price; share count
Insolvency statusCIRP admitted 15 Apr 2026, CP(IB) No. 91/BB/2025, NCLT Bengaluru; IRP T. Narayana Swamy (Reg. IBBI/IPA-002/IP-N01078/2020-2021/13427)NCLT order; exchange filings
Websitehttps://www.vivimedlabs.comForm G

Vivimed Labs is a Hyderabad-managed, Bidar-registered Indian pharmaceutical manufacturer that once operated as a globally diversified specialty chemicals and API group, with subsidiaries in the UK (James Robinson), Spain and Mexico (UQUIFA), Hungary (Soneas), and the US. Over the last decade it has progressively dismantled that portfolio: selling specialty chemical product lines to Clariant (2015), exiting its US generics joint venture to Strides (2019), and ceasing to consolidate its European API arm around FY2022. What remains is a sub-scale domestic finished-dosage and API manufacturer with five plants across Telangana, Uttarakhand and Karnataka, revenue from operations of INR 699.9 million in FY2026 (down from INR 8.6 billion consolidated in FY2021), negative net worth, defaulted bank debt assigned to an asset reconstruction company, a pending CBI bank-fraud investigation (stayed by the Telangana High Court), and an active CIRP. The equity is effectively an option on a resolution outcome.


What the company does today

On the basis of its most recent statutory and insolvency disclosures, Vivimed Labs is today primarily a manufacturer of pharmaceutical dosage forms and active pharmaceutical ingredients (APIs). The IRP's Form G (14 June 2026) describes the corporate debtor as operating in the business of manufacturing pharma dosage forms at Hyderabad, Haridwar, Kashipur and Bidar. Aggregator and exchange descriptions characterise the company as engaged in APIs, contract development and manufacturing (CDMO), finished dosage formulations (FDF), specialty chemicals and retail branded formulations.

The company's own description

Vivimed's legacy self-description (2019 investor presentations) framed the group around three pillars — "Leveraging Global Presence," "Partnering Innovation," and "Delivering Affordable Chemistry" — and around two businesses: (i) a pharmaceuticals business anchored by UQUIFA (API and CDMO, with Spain, Mexico, Hungary and India operations, USFDA-approved sites) plus Indian FDF; and (ii) a specialty chemicals business (hair dyes, photochromic dyes, anti-microbials, imaging chemicals), which in 2019 the company itself labelled as "under divestment." A more recent company description (repeated by brokers) states that Vivimed manufactures APIs, intermediates and nutraceutical ingredients with an export orientation, and supports innovator pharma companies through custom synthesis from gram scale for clinical trials through launch and life-cycle management. That description appears to reflect the UQUIFA-era CDMO franchise and is likely outdated relative to the current asset base.

Independent characterisation

Our independent characterisation is that Vivimed is now a distressed, sub-scale Indian contract and own-brand formulations manufacturer whose revenue has fallen roughly 92% in five years (consolidated revenue from operations from ~INR 8,615 million in FY2021 to INR 699.9 million in FY2026). Its business model is predominantly product sales (manufactured formulations and APIs, including likely loan-licence and third-party manufacturing), with no meaningful subscription, licensing or service income disclosed. Its historic value-chain position spanned the middle of the pharma chain — API/intermediate synthesis and finished dosage manufacturing — selling to generic drug companies, innovators (CDMO) and distributors in India and export markets. Today, with working capital starved (inventory fell from INR 2,408 million in FY2022 to INR 127 million in FY2026), the plants are almost certainly operating far below installed capacity.

Revenue model mix

Revenue typeHistoric (to FY2021)Current (FY2026)Comment
Product sales — APIs / intermediatesMajor (via UQUIFA)Minor/unclearUQUIFA no longer consolidated (see §3, §11)
Product sales — finished dosage formsMeaningfulDominantForm G describes the business as dosage-form manufacturing
CDMO / custom synthesis servicesMeaningful (UQUIFA, Soneas)—Likely negligible post-deconsolidation
Specialty chemicalsDominant pre-2015; "under divestment" by 2019—Residual activity, if any, undisclosed
Licensing / royalties———
Other revenue—INR 63.19 million (FY2026)S&P classification "other revenue"

Customer types and end-markets

Customer types historically included global generic pharmaceutical companies (API buyers), innovator pharmaceutical companies (CDMO), personal-care and cosmetics majors (hair dyes, anti-microbials), ophthalmic lens makers (photochromic dyes), Indian pharma marketers (contract formulation), and government/export registrations (e.g., Uzbekistan product approvals in 2021). Current customer concentration is not disclosed.

Strategy

Stated strategy (historic)

Vivimed's last articulated strategy (2019 investor presentations) rested on three themes: leveraging global presence through UQUIFA and Soneas; partnering on innovation (CDMO for innovators, the Strides ANDA JV); and delivering affordable chemistry (cost-efficient API and formulation supply). The 2015 Clariant divestment statement explicitly set the direction: use proceeds to cut debt and refocus on pharmaceutical APIs and finished dosage forms in regulated markets. None of these strategies remains executable.

Initiatives in the last 24 months (Oct 2024 – Oct 2026)

DateInitiativeStatus
Jan 2025 onwardCompliance catch-up: delayed results filed; CFO appointed; revocation of trading suspension soughtAchieved — trading resumed 18 Dec 2025
2,025Debt restructuring/settlement proposals to SBI-led lenders (ongoing since 2021)Failed — SBI assigned debt to Rare ARC (Oct 2025)
10 Dec 2025Extraordinary General MeetingHeld via VC/OAVM
12 Feb 2026Debtor-initiated Pre-packaged Insolvency Resolution Process (PPIRP) application under s.54A IBCOvertaken by creditor-initiated CIRP (15 Apr 2026)
14 Jun 2026 onwardIRP-run resolution process: Form G, PRA lists, information memorandum, resolution plans due 28 Aug 2026Ongoing

No transformation programme, ESG commitment, cost programme with targets, or medium-term financial guidance has been published. Management guidance: none. In CIRP, the effective "strategy" is the CoC's selection of a resolution applicant (or, failing that, liquidation).

Products & Services

The company has not published a current product catalogue in any verifiable filing since its 2019 investor materials. The catalogue below distinguishes clearly between current (verified via 2026 insolvency documents) and legacy offerings.

Pharmaceuticals — current

Product / offeringDescriptionTarget customerStatus / yearPricing
Finished dosage forms (tablets, capsules and other oral forms)Manufactured at Hyderabad (2 units), Haridwar, Kashipur and BidarIndian pharma marketers, own brands, exportsCurrent (Form G, June 2026)—
APIs and intermediates (India)Bulk drug manufacturing (industry classification: "Pharmaceuticals – Indian – Bulk Drugs & Formulations")Generic manufacturersCurrent scale not disclosed—
Retail branded formulationsDomestic branded genericsIndian trade channelReferenced in aggregator descriptions—
Export registrations — UzbekistanApprovals in 2021 for products including Bilastine tablets and an Orzole combination, from PIC/S- and Health Canada-approved siteCIS government/importers2021 approvals; current sales not disclosed—
FavipiravirOral antiviral (COVID-19 era) approval received in 2021Domestic/export2021; likely discontinued commercially—

Installed capacity, quantity and value of main products sold in FY2026 were not legibly verifiable from the Form G copy retrieved; the IRP noted the FY2026 audit had not been finalised at Form G publication.

Pharmaceuticals — legacy (UQUIFA era)

OfferingDescriptionStatus
UQUIFA generic APIsAPI portfolio including anti-ulcer and antidepressant compounds; USFDA-approved Spanish sites; ~80 years of operating historyNo longer consolidated (from ~FY2022)
UQUIFA / Soneas CDMOCustom synthesis from gram-scale through commercial supply for innovators; Hungarian development capabilitiesSame as above
US ANDA portfolio (Strides JV)10 approved ANDAs; Alathur oral solids plantSold to Strides 2019 for INR 75 crore

Specialty chemicals — legacy

Product lineDescriptionStatus
Hair dyes / hair colorantsOxidative dye intermediates for hair-care majorsPortion sold to Clariant (2015); remainder status undisclosed
Photochromic dyesDyes for ophthalmic lenses; company claimed world leadership and patented processesLabelled "under divestment" in 2019
Anti-microbialsPreservatives/actives for personal and industrial careSame
Imaging chemicalsPhotographic/imaging intermediatesSame
Home and personal care ingredients (oral care, sun care, skin care)Ingredients supplied to FMCGSame

Financial Narrative

All figures consolidated, INR millions, from S&P Global Market Intelligence via StockAnalysis.com (data updated after the FY2026 results filed 17 July 2026) unless noted. "Revenue" = total revenue including other revenue; "Revenue from operations" shown separately. Ratios marked are analyst calculations.

Income statement

FY2021 reference point: consolidated net sales INR 8,614.7 million and net loss INR 778.0 million (Capital Market/IIFL, FY2022 results coverage). The FY2026 consolidated net loss is reported by the company as INR 1,764.72 million.

Margins

Revenue from operations CAGR FY2022–FY2026: -26.3% per year (analyst calculation: (699.89/2373)^(1/4) − 1). FY2021–FY2026 CAGR (on INR 8,614.7M base): approximately -39% per year.

Commentary. The five-year income statement describes a business in continuous contraction with two step-downs. The first, in FY2022, was structural: revenue fell 72% as the UQUIFA group dropped out of the consolidation. The second, in FY2023, was a clean-up year: a negative gross profit (cost of revenue INR 2,746 million against revenue of INR 1,881 million) and an INR 892.8 million asset write-down point to large inventory write-offs — inventory fell from INR 2,408 million to INR 798 million in a single year. FY2024 and FY2025 showed apparent gross-margin "recovery" to ~49–55%, but this flattered by low revenue, absent interest accrual, and possibly by mix; operating losses persisted because the fixed-cost base (five plants, ~550 employees) could not be absorbed. FY2026 is the most severe operating year: gross margin collapsed to 3.4%, other operating expenses jumped to INR 1,237 million (from INR 388 million), and goodwill of INR 169 million disappeared from the balance sheet — consistent with large Q4 provisions and impairments taken ahead of or alongside the CIRP. Q3 FY2026 alone showed revenue of only INR 159.9 million and a loss of INR 165.5 million; the implied Q4 FY2026 loss (from aggregator EPS of approximately INR 17.74 per share for the quarter) is roughly INR 1.47 billion, which should be treated as an analyst inference pending review of the full results notes.

Balance sheet

Commentary. Net debt has been essentially flat at ~INR 3.5–4.0 billion for five years because no principal has been repaid and new borrowing has been negligible, but equity has been wiped out by cumulative losses of ~INR 6.5 billion (FY2022–FY2026). Net worth turned negative in FY2024 and reached INR −2.1 billion in FY2026 — before adjusting for ~INR 0.6 billion per year of unrecorded interest. The INR 1.49 billion of intangibles and INR 1.8 billion of long-term investments are of doubtful recoverable value in an insolvency context, implying tangible book value of approximately INR −3.6 billion (S&P). The default amount declared in the PPIRP filing — INR 5,125.3 million as of 31 January 2026 — is materially higher than the INR 3,748 million of borrowings in default cited in mid-2025, the difference presumably being accumulated interest and charges.

Cash flow

Commentary. Positive operating cash flow in FY2022, FY2023 and FY2026 was generated almost entirely by liquidating working capital (inventory and receivables), not by profitable operations — in FY2023, INR 1.61 billion came from inventory reduction, and in FY2026, INR 460 million from inventory and INR 288 million from receivables. This is the cash-flow signature of a business winding down its balance sheet. Capex has fallen to near zero (INR 9.5 million in FY2026 against D&A of INR 260 million), meaning the asset base is being consumed without reinvestment — a material concern for GMP compliance at regulated sites.

Ratios

Notes: ROE for FY2024–FY2026 is entered as 0 because equity was negative and the ratio is not meaningful. ROIC is not meaningful given negative EBIT and negative equity. All ratios are analyst calculations from S&P data.

Commentary. Every solvency metric is in distress territory. The current ratio of 0.37 in FY2026 and working capital of INR −2.8 billion confirm the company cannot meet current obligations. The apparent improvement in the cash conversion cycle to 36 days in FY2026 is not operational excellence; it reflects inventory being run down to INR 127 million and suppliers being stretched to ~264 payable days — a pattern consistent with the operational creditor petition (Blue Cube/Dow perchloroethylene supplies) that ultimately triggered the CIRP. Receivable days of ~236 suggest either weak collection or doubtful debts; Screener flagged high debtor days and contingent liabilities of INR 1.83 billion.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment (Historic Definition) Overview

Segment (historic definition)What it containedStatus today

Pharmaceuticals

UQUIFA APIs and CDMO (Spain, Mexico, Hungary, India); Indian FDF plants; retail branded formulations; US ANDA JV (until 2019)

Indian FDF/API plants remain; UQUIFA not consolidated

Specialty Chemicals

Hair dyes, photochromic dyes, anti-microbials, imaging chemicals; James Robinson (UK)

Identified lines sold to Clariant (2015); remainder "under divestment" (2019); current status not disclosed

Revenue by Segment and Segment Margins & Growth (%)

MetricFY2024FY2025FY2026

Consolidated revenue from operations (INR Mn)

1,4911,163699.89

YoY growth (%)

-20.3-22.0-39.8

Operating income (INR Mn)

-418.07-288.5-1,722

Operating margin on total revenue (%)

-26.29-23.91-225.62

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Revenue from operations (INR Mn)

2,3731,8711,4911,163699.89

Total revenue (INR Mn)

2,3861,8811,5901,206763.08

Gross profit (INR Mn)

828.14-864.86867.76590.2125.61

Operating income / EBIT (INR Mn)

-250.73-2,051-418.07-288.5-1,722

EBITDA (INR Mn)

-67.91-1,859-218.66-86.26-1,461

Depreciation & amortisation (INR Mn)

182.82191.27199.41202.24260.52

Interest expense, reported (INR Mn)

385.42350.0412.1317.3541.7

Asset write-down (INR Mn)

0892.8000

Pre-tax income (INR Mn)

-648.33-3,307-458.23-318.48-1,763

Net income (INR Mn)

-676.5-3,285-454.46-319.61-1,765

EPS basic (INR)

-8.16-39.62-5.48-3.85-21.15

EPS diluted (INR)

-8.16-39.62-5.48-3.85-21.15

Dividends per share (INR)

00000

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Gross margin (%)

34.72-45.9954.5648.923.36

Operating margin (%)

-10.51-109.03-26.29-23.91-225.62

EBITDA margin (%)

-2.85-98.86-13.75-7.15-191.48

Net margin (%)

-28.36-174.69-28.57-26.49-231.26

Balance Sheet and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (INR Mn)

12,6609,9519,5099,2087,535

Cash & equivalents (INR Mn)

71.8437.6220.267.0813.56

Accounts receivable (INR Mn)

873.64741.56828.2741.1453.33

Inventory (INR Mn)

2,408797.6640.62587.55127.15

Property, plant & equipment (INR Mn)

4,0262,9882,8352,7152,548

Goodwill (INR Mn)

169.14169.14169.14169.140

Other intangibles (INR Mn)

1,4041,4071,3821,3641,486

Goodwill & intangibles total (INR Mn)

1,573.141,576.141,551.141,533.141,486

Long-term investments (INR Mn)

1,9881,9881,6851,6851,805

Short-term debt incl. current LTD (INR Mn)

2,9793,1633,1343,1273,258

Long-term debt (INR Mn)

609.93623.19635.65636.15715.1

Total debt (INR Mn)

3,5893,8103,7883,7633,973

Net debt (INR Mn)

3,5173,7733,7683,7563,960

Other long-term liabilities (INR Mn)

4,4774,5354,6764,7114,354

Total liabilities (INR Mn)

9,0179,5569,5649,5609,640

Shareholders' equity (INR Mn)

3,643394.22-54.61-351.69-2,106

Working capital (INR Mn)

1,339-851-677.42-806.44-2,801

Book value per share (INR)

43.944.75-0.66-4.24-25.39

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow (INR Mn)

275.4353.22-239.91-17.5177.03

Capital expenditure (INR Mn)

-164.1-49.68-20.39-45.31-9.47

Free cash flow (INR Mn)

111.3303.54-260.3-62.8267.56

Cash interest paid (INR Mn)

397.6359.0324.3229.4741.7

Net debt issued / (repaid) (INR Mn)

293.8221.21-3679.11-19.36

Dividends paid (INR Mn)

00000

Share buybacks (INR Mn)

00000

Change in working capital (INR Mn)

337.732,217-150.3666.371,529

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

ROE (%) — negative equity years not meaningful

-18.57-833.3000

ROA, net income / year-end assets (%)

-5.34-33.01-4.78-3.47-23.42

Current ratio (x)

1.360.80.830.80.37

Debt / equity (x) — negative = negative equity

0.999.66-69.36-10.7-1.89

Net debt / EBITDA (x) — negative EBITDA, not meaningful

-51.79-2.03-17.23-43.54-2.71

Interest coverage, EBIT / reported interest (x)

-0.65-5.86-34.47-16.63-41.29

Asset turnover, revenue / assets (x)

0.190.190.170.130.1

Receivable days (DSO, on revenue from ops)

134.4144.7202.7232.6236.4

Inventory days (DIO, on cost of revenue)

564.5106323.534862.9

Payable days (DPO, on cost of revenue)

98.273.4222.6233.5263.5

Cash conversion cycle (days)

600.7177.3303.6347.135.8

Revenue by Region

MetricFY2024FY2025FY2026

Total consolidated revenue from operations (INR Mn)

1,4911,163699.89

Share Price History

DatePrice (INR)ContextSource

30 Sep 2015

~342–348 (face value INR 10, pre-split)

Clariant deal announcement

Business Standard

28 Mar 2022

14.75 (52-week low 14.60)

SBI forensic audit

Business Standard

19 Jan 2023 – 17 Dec 2025

Suspended (limited trade-for-trade windows)

Reg. 34 non-compliance

NSE

Dec 2025 – Jan 2026

52-week high 29.40

Post-relisting speculative spike

Value Research

8 Jun 2026

6.52

Post-CIRP admission

Value Research

26 Jul 2026

5.18—

Chola Securities

52-week low (2026)

5.15—

Value Research

23 Sep 2026

5.30—

Multibagg

7 Oct 2026

6.59

Latest close

StockAnalysis

Valuation Snapshot

MultipleValueComment

Market capitalisation

INR 546.5M (INR 54.65 crore)

82.93M shares × INR 6.59

Enterprise value

~INR 4,506M

Mcap + FY2026 net debt INR 3,960M (excludes unrecorded interest and INR 4.35B other LT liabilities)

EV/Sales

~6.4x

On FY2026 revenue from operations INR 699.89M

P/B

Not meaningful (negative book value INR −25.39/share consolidated)

Aggregators show −0.3x to −1.6x depending on standalone/consolidated basis

Capital Markets

ItemStatus

Analyst consensus

None — no sell-side coverage; MarketsMOJO quantitative rating "Strong Sell"

Debt maturity profile

Effectively all debt in default and payable on demand; short-term debt INR 3,258M, long-term INR 715M (FY2026)

Trading series

BE (trade-for-trade settlement) since 18 Dec 2025

Analyst Conclusions

Guidance and consensus

There is no management guidance (the board is suspended) and no consensus estimate. The relevant forward calendar is the CIRP timeline: resolution plans were due 28 August 2026; the CoC has met at least seven times (latest 10 September 2026); the statutory 180-day period from 15 April 2026 expires around 12 October 2026, extendable to a maximum of 330 days (including litigation time) — i.e., to approximately March 2027.

Bull case (grounded arguments)

  1. Asset value exceeds equity price: PP&E of INR 2.55 billion across five licensed plants contrasts with a market capitalisation of ~INR 0.55 billion; a resolution plan that preserves even a sliver of equity could re-rate the stock.

  2. MSME eligibility and ARC creditor: MSME status (Form G corrigendum) potentially widens the applicant pool, and Rare ARC — having bought SBI's exposure at a discount — may accept a pragmatic plan.

  3. Legal overhang may lift: Telangana HC has already suspended the fraud classification and stayed CBI coercive steps; final relief would remove a key deterrent for bidders.

Bear case (grounded arguments)

  1. Equity is structurally subordinated: claims (default of INR 5.1 billion as of January 2026, plus operational creditors and contingent liabilities of INR 1.8 billion) dwarf any plausible asset recovery; IBC plans routinely extinguish or massively dilute existing shares.

  2. Operations are failing: FY2026 revenue fell 40% to INR 0.7 billion with EBITDA of INR −1.46 billion and gross margin of 3.4%, so the going-concern value is eroding during the process.

  3. Liquidation risk is real: with near-zero capex, uncertain plant compliance and a criminal investigation overhang, bidder interest may be thin; failure to secure an approved plan leads to liquidation.

Catalysts and monitorables (next 12 months)

CatalystExpected timingWhy it matters
Disclosure of resolution plans received / CoC voteQ4 CY2026Determines equity treatment
CIRP extension application (beyond 180 days)~Oct 2026Signals process health
NCLT approval of any resolution planCY2027Change of control; possible capital reduction
Telangana HC final orders on CBI/SBI fraud mattersOngoingBidder confidence; promoter eligibility
FY2026 AGM (extended by up to 3 months)By ~Dec 2026Compliance continuity
Q1/Q2 FY2027 results under IRPQ4 CY2026Run-rate erosion
Any liquidation applicationContingentWorst case for equity

Analyst verdict

Vivimed Labs is no longer an operating-company investment case; it is an insolvency case. Over roughly a decade the group went from a globally diversified specialty chemicals and API platform — with UK, Spanish, Mexican, Hungarian and US operations, a USFDA-approved API franchise and a US generics JV — to a sub-scale, India-only formulations manufacturer with five under-utilised plants, revenue from operations of INR 0.7 billion and an EBITDA loss of INR 1.46 billion in FY2026. The decline was not a single shock: leverage taken on to fund acquisitions was never adequately reduced despite the Clariant (2015) and Strides (2019) disposals; the COVID period pushed the SBI account into NPA status in 2021; the European API arm left the consolidation around FY2022; and governance failures — missed annual reports, a three-year trading suspension, qualified audits, and a CBI investigation — destroyed lender and investor trust.

Since 15 April 2026 the company has been under CIRP, run by an IRP and governed by its creditors. The defining question is not earnings power but recovery waterfall. On reported numbers, consolidated net worth is INR −2.1 billion before roughly INR 0.6 billion of unrecorded annual interest, while the declared default was INR 5.1 billion in January 2026. Against that, the hard-asset base (PP&E ~INR 2.5 billion) is unlikely to cover secured and operational claims in full, implying that existing equity will probably be extinguished or diluted to a nominal stake in any approved plan.

The share price (INR 6.59, market capitalisation ~INR 55 crore) therefore represents a speculative option on an unusually generous resolution outcome. For institutional purposes we classify the equity as uninvestable / avoid, with relevance limited to distressed-asset buyers evaluating the plants as a resolution applicant, and to creditors monitoring recovery. Key watchpoints are the CoC's plan selection, any CIRP extension, and final High Court orders on the fraud and CBI matters.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleTenureBackground / notes

Santosh Varalwar

Managing Director (promoter)

Director since 9 Nov 1989; MD re-appointed for 5 years w.e.f. 14 Aug 2020 (term to 13 Aug 2025; renewal proposed at AGM)

Founder-promoter; led the 2008–2018 acquisition strategy; also director of BBR Projects Pvt Ltd, UQUIFA India Pvt Ltd and others; named petitioner in Telangana HC proceedings vs CBI/SBI

Dr. Manohar Rao Varalwar

Whole-Time Director (promoter)

WTD since 14 Aug 2015 (associated since inception)

Promoter-family elder

Sandeep Varalwar

Whole-Time Director (promoter)

—

Promoter family

Aparna Bidarkar

Director

Since 11 Dec 2024

—

Jarugula Siva Prasad

Director

Since 11 Dec 2024

—

Subbarathnamma Palepu

Director (independent, per MCA listing)

——

Hari Gopal Jamalapuram

Independent Director

Died 18 Nov 2024

—

Umanath Varahabhotla

Independent Director (former)

—

Listed in older profiles

Phaninder Nath P S

Chief Financial Officer

Appointed 10 Jan 2025; resigned citing health (early 2026)

Received CBI notice Jan 2026

Yugandhar Kopparthi

Company Secretary

Current

Received CBI notice Jan 2026

Mark Robbins

CEO, UQUIFA (historic)

Joined with UQUIFA acquisition 2011

No longer relevant post-deconsolidation

Major Shareholders

Holder categoryStake (latest available)Source / date

Promoters & promoter group

~7.6% (7.57%–7.77% across sources)

Share.market 28 Aug 2026; Chola; Screener

Foreign institutional investors

~1.6%

Share.market Aug 2026

Domestic institutional investors

~0.2%

Share.market Aug 2026

Public / non-institutional

~90.7%

Share.market Aug 2026

Competitive Landscape

Peer Comparison FY2026

DimensionVivimed (FY2026)Typical listed small/mid Indian pharma peer

Revenue from operations

INR 699.89M

Generally INR several billion to tens of billions (an order of magnitude or more larger)

Revenue growth

-39.8% YoY

Typically positive single to low double digits

EBITDA margin

-191.5%

Typically positive, mid-teens to twenties

R&D intensity

Not disclosed; likely negligible

Typically 1–8% of revenue

Balance sheet

Negative equity; in CIRP

Solvent; most net-cash or moderately levered

Recent Developments

--

Company Snapshot

$8.8M

Revenue

552

Employees

1988

Founded

Karnataka, India

Headquarters

SWOT Analysis

Strengths

  • Multi-site manufacturing base: five plants (2 Hyderabad, Haridwar, Kashipur, Bidar) per Form G (June 2026), providing a ready-made platform for an acquirer.
  • Hard asset backing: PP&E of INR 2,548 million (FY2026), including land of ~INR 1,099 million and buildings of ~INR 1,218 million (FY2025 breakdown).
  • Regulatory heritage: historic PIC/S and Health Canada site approvals and 2021 Uzbekistan GMP extension with five new registrations.
  • Trading restored: suspension revoked 18 Dec 2025, enabling price discovery and any future equity-linked resolution.
  • MSME status: confirmed in the Form G corrigendum (20 Jun 2026), which may broaden the eligible resolution-applicant pool under Section 240A IBC.

Weaknesses

  • Insolvency: CIRP since 15 Apr 2026; board powers suspended.
  • Negative net worth: equity INR −2,106 million (FY2026 consolidated), before ~INR 626 million of unrecorded interest.
  • Revenue collapse: revenue from operations down from INR 2,373 million (FY2022) to INR 699.89 million (FY2026); 4-year CAGR −26.3%.
  • Deep operating losses: FY2026 EBITDA INR −1,461 million; gross margin 3.4%.
  • Audit qualifications: FY2025 (unrecorded interest INR 574.44 million; no bank confirmations) and FY2026 (INR 625.72 million).
  • Governance record: annual reports for FY2021 and FY2022 not filed on time, leading to suspension from 19 Jan 2023 to 18 Dec 2025.

Opportunities

  • Resolution-plan revaluation: a credible applicant could recapitalise the plants; resolution plans were due 28 Aug 2026.
  • Asset-light utilisation: idle capacity could be leased to Indian formulation marketers through contract manufacturing.
  • Legal relief: Telangana HC stays on SBI's fraud classification (W.P. 24697/2025) and on CBI coercive action (6 Feb 2026) could, if made final, remove a resolution barrier.
  • ARC-driven settlement: with SBI debt now with Rare ARC (Oct 2025), a discounted settlement is more plausible than with a public-sector bank.
  • Industry tailwinds: Indian generics and CDMO demand remains structurally strong for a recapitalised operator.

Threats

  • Liquidation: if no plan is approved within the CIRP timeline (180 days to ~12 Oct 2026, extendable to 330 days), the NCLT may order liquidation — equity would likely be wiped out.
  • Criminal proceedings: CBI case RC 03(E)/2025 and SBI fraud classification; adverse rulings could disqualify promoters and deter bidders.
  • Equity dilution/extinguishment: IBC resolution plans commonly cancel or heavily dilute existing shares.
  • Multiple creditor claims: the NCLT noted multiple pending insolvency petitions; the PPIRP filing cited a default of INR 5,125.3 million.
  • GMP obsolescence: capex of INR 9.5 million in FY2026 against D&A of INR 260.5 million erodes plant compliance.
  • Contingent liabilities: INR 1.83 billion flagged (Screener), plus INR 4.35 billion of other long-term liabilities of undisclosed nature.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
13 May 2025Board meeting called for 30 May 2025 to approve FY2025 audited resultsCompliance resumption
30–31 May 2025FY2025 results: consolidated loss ~INR 320M; borrowings in default INR 3,744.56M; qualified opinion; going-concern uncertaintyFormal distress acknowledgement
13 Jun 2025Disclosure that INR 3,744.56M borrowings were unconfirmed (no bank confirmations) and net loss understatedAudit integrity concern
Aug 2025 (approx.)Q1 FY2026 results; default INR 3,748.22M; all loan accounts NPA; director and auditor re-appointments approvedContinued stress
2025Telangana HC (W.P. 24697 of 2025) suspended SBI's fraud classificationLegal relief
25 Oct 2025SBI exposure assigned to Rare ARCCreditor changes to ARC
13 Nov 2025H1 FY2026 results board meeting; intimation regarding pre-pack routeRestructuring signal
19 Nov 2025CBI registers RC 03(E)/2025Criminal investigation
21 Nov 2025EGM notice dispatched—
10 Dec 2025EGM held; NSE circular revoking trading suspensionRe-listing
18 Dec 2025Trading resumes on BSE/NSE (BE series, trade-for-trade)Liquidity restored after ~35 months
5–6 Jan 2026Exchanges seek clarification on sharp price movement; company says market-drivenSpeculative trading (52-week high INR 29.40)
20 Jan 2026CBI search and seizure at premises (Bengaluru and New Delhi BS&F branches)Escalation
27–29 Jan 2026CBI notice to CFO and CSOfficers drawn in
3 Feb 2026Exchange disclosure of CBI notice and Rare ARC assignmentTransparency
6 Feb 2026Telangana HC grants interim stay on CBI coercive steps; hearing listed 6 Mar 2026Temporary relief
12 Feb 2026PPIRP application filed at NCLT Bengaluru; default INR 5,125.3M as of 31 Jan 2026Debtor seeks pre-pack
13 Feb 2026Q3 board meeting cancelledCompliance slippage
Early 2026CFO Phaninder Nath P S resigns citing healthKMP attrition
13 Mar 2026Q3 FY2026 results: revenue INR 159.9M; loss INR 165.5M; unaccrued interest INR 164.52M (Q) / INR 472.37M (9M); provision INR 46.03MLosses widen
6 Apr 2026Promoters confirm no FY2026 encumbrancesDisclosure
15 Apr 2026NCLT Bengaluru admits CIRP (Blue Cube Germany Assets, INR 2.79 crore); moratorium; IRP appointedControl shifts to IRP
17 Apr 2026Company receives order; discloses admission—
23 Apr 2026Public announcement; claims due 1 May 2026Claims process
13 May 2026First CoC meetingCreditor governance begins
28–30 May 2026FY2026 results board meetings twice postponedDelay
14 Jun 2026Form G published (EOI deadline 29 Jun 2026)Sale process
18 Jun 2026Third CoC meeting—
20 Jun 2026Form G corrigendum (MSME registration status)Eligibility nuance (s.240A IBC)
4 Jul / 20 Jul 2026Fourth and fifth CoC meetings—
9 Jul / 24 Jul 2026Provisional / final PRA lists due—
17 Jul 2026FY2026 audited results: net loss INR 1,764.72M; revenue INR 699.89M; qualified for unrecorded interest of INR 625.72MDeep losses
29 Jul 2026Information memorandum / RFRP issue date—
18 Aug 2026Sixth CoC meeting—
28 Aug 2026Resolution plan submission deadlineKey milestone
10 Sep 2026Seventh CoC meetingLikely plan evaluation
25–26 Sep 2026CoC approves application to RoC Bangalore for 3-month AGM extensionAGM delayed
~12 Oct 2026Imminent milestone

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

3 charts
Income Statement: Revenue & Gross Profit: Total revenue fell from INR 2,386 Mn in FY2022 to INR 763.1 Mn in FY2026.
Vivimed Labs Ltd — Income Statement: Revenue & Gross Profit
Series (INR Mn)FY2022FY2023FY2024FY2025FY2026
Total revenue2,3861,8811,5901,206763.1
Revenue from operations2,3731,8711,4911,163699.9
Gross profit828.1-864.9867.8590.225.6

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.